Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
Why the study?
Prior monotherapy studies showed zilebesiran reduced serum angiotensinogen and systolic blood pressure, but its efficacy and safety when added to standard antihypertensive medication required evaluation.
Does a single subcutaneous dose of zilebesiran reduce 24-hour mean ambulatory SBP at 3 months in adults with uncontrolled hypertension on standard therapy?
Population
663 adults with uncontrolled hypertension across 8 countries
Comparison
Single-dose zilebesiran 600 mg vs matching placebo added to standard antihypertensives
Design
Phase 2 prospective double-blinded randomized trial
Follow-up
3 months
Authors
Discussion
Loading...
Member takes
Implication
Zilebesiran add-on yields further SBP reductions in uncontrolled hypertension; extends monotherapy data to combination regimens in phase 2.
Structured PICO
Does a single subcutaneous dose of zilebesiran reduce 24-hour mean ambulatory SBP at 3 months in adults with uncontrolled hypertension on standard therapy?
P
Population
663 adults with uncontrolled hypertension (24-hour mean ambulatory SBP 130-160 mm Hg) despite open-label run-in treatment with indapamide, amlodipine, or olmesartan. Multinational (150 sites across 8 countries).
I
Intervention
Single subcutaneous dose of zilebesiran 600 mg added to standard antihypertensive medication (indapamide 2.5 mg, amlodipine 5 mg, or olmesartan 40 mg once daily)
C
Comparator
Matching placebo added to standard antihypertensive medication (indapamide 2.5 mg, amlodipine 5 mg, or olmesartan 40 mg once daily)
O
Outcome
Difference between zilebesiran and placebo in change from baseline in 24-hour mean ambulatory SBP at 3 monthssurrogate
In patients with uncontrolled hypertension on standard therapy, a single subcutaneous dose of zilebesiran significantly reduced systolic blood pressure at 3 months.
Cite This Study
Desai et al. (2025) studied this question.